课题基金 / 基金详情

Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors

Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
研究 Max 作为小细胞肺癌和其他神经内分泌肿瘤的抑癌基因
批准号:
10400844
负责人:
Robert Neil Eisenman
金额:
$54.4万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-05-01 至 2025-04-30

项目摘要

项目成果

Robert Neil Eisenman的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 转录调节因子MYC家族的异常表达是广泛的 人类癌症的谱系,包括小细胞肺癌(SCLC),一种高度侵袭性的神经内分泌- 一种肿瘤,是美国癌症死亡的主要原因之一。特异性MYC家族蛋白 与MAX异源二聚,以结合基因组DNA并刺激广泛的转录。令人惊讶的是, 最近的报告显示,MAX通过删除和截断突变在一个重要的子集 小细胞肺癌和其他神经内分泌癌。自相矛盾的是,麦克斯可能是一种肿瘤抑制因子,但实际上 对小细胞肺癌的MYC致癌性至关重要,这对于我们理解这些疾病的病因具有重要的意义。 肿瘤,但尚未进行系统研究。这项建议是基于我们两人的研究结果 实验室发现(I)癌前小细胞肺癌(Prescs)的全基因组CRISPR失活筛查 MAX靶向的sgRNAs是高度促进生长的;和(Ii)MAX的缺失显著加速了SCLC 在一个原生小鼠模型中。这些结果首次为生物系统提供了高度相关的 阐明MAX的肿瘤抑制功能。 在目标1中,我们将表征MAX缺失的小细胞肺癌的生物学特性,包括增殖、凋亡 和基因组的稳定性。此外,我们将使用ChIP-Seq和RNA-Seq来确定 小细胞肺癌中MYC/MYCL和MAX结合及靶基因表达我们将在功能上 询问通过综合基因组分析确定的关键MAX目标基因的重要性。目标为 研究将包括已确定的一种碳代谢的MAX依赖调节因子。AIM 2是基于 关于MAX缺失不仅改变MYC活动而且扰乱更广泛的MYC-MAX的假设 激活因子和抑制因子的转录网络。我们将确定MYC/MYCL是否有MAX独立 在我们的小细胞肺癌模型和人小细胞肺癌细胞系中的致癌功能,并检查网络成员 对抗或与MYC合作(如MXD/MNT、MLX和Mondoa),影响SCLC 进步。在目标3中,我们建议确定核心MAX调节的基因和共同的途径 MAX对神经内分泌肿瘤的抑制作用这将需要我们新的分子和基因特征 最大缺失(Rb/P53)所致甲状腺髓样癌和嗜铬细胞瘤模型 不足的背景)以及与Max-Null SCLC共享的通路的识别。这项研究将扩大 我们的研究范围广泛,以揭示MAX是如何抑制神经内分泌癌的。我们预计这些 研究将加深我们对MYC网络在驱动和抑制中的复杂作用的理解 并确定可能成为治疗靶点的新的肿瘤形成途径。
英文摘要
SUMMARY Dysregulated expression of the MYC family of transcriptional regulators is a common denominator in a wide spectrum of human cancers, including small cell lung carcinoma (SCLC), a highly aggressive neuroendocrine- type tumor that is among the leading causes of US cancer mortality. MYC family proteins specifically heterodimerize with MAX in order to bind genomic DNA and stimulate widespread transcription. Surprisingly, recent reports show that MAX is inactivated through deletions and truncating mutations in a significant subset of SCLC and other neuroendocrine cancers. The paradox that MAX may act as a tumor suppressor, but yet be crucial for MYC oncogenicity in SCLC, has important implications for our understanding of the etiology of these tumors but has not been systematically investigated. This proposal is based on the findings from our two laboratories that (i) a whole-genome CRISPR inactivation screen in pre-neoplastic SCLC (preSCs) revealed MAX-targeting sgRNAs to be highly growth promoting; and (ii) deletion of MAX dramatically accelerates SCLC in an autochthonous mouse model. These results provide, for the first time, highly relevant biological systems to elucidate MAX's tumor suppressor function. In Aim 1 we will characterize the biological properties of MAX-deleted SCLC including proliferation, apoptosis and genomic stability. Moreover, we will use ChIP-Seq and RNA-Seq to determine the genomic landscape of MYC/MYCL and MAX binding and target gene expression in SCLC and MAX-deleted SCLC. We will functionally interrogate the importance of key MAX target genes identified through integrative genomic analyses. Targets to be studied will include MAX-dependent regulators of one carbon metabolism already identified. Aim 2 is based on the hypothesis that MAX deletion not only alters MYC activity but disrupts the broader MYC- MAX transcriptional network of activators and repressors. We will determine if MYC/MYCL have MAX independent oncogenic functions in our SCLC models and in human SCLC cell lines, and examine whether network members that antagonize or cooperate with MYC (such as MXD/MNT, MLX, and MondoA), act to influence SCLC progression. In Aim 3 we propose to determine core MAX-regulated genes and pathways common to neuroendocrine tumor suppression by MAX. This will entail molecular and genetic characterization of our new models of thyroid medullary carcinomas and pheochromocytomas resulting from MAX loss (in an Rb/p53 deficient background) and identification of pathways shared with MAX-null SCLC. This research will extend the breadth of our studies to uncover how MAX suppresses neuroendocrine cancers. We anticipate that these studies will deepen our understanding of the complex role of the MYC network in both driving and suppressing neoplasia and identify novel tumorigenic pathways that may have the potential to serve as therapeutic targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
  • 批准号:
    10662195
  • 项目类别:
  • 资助金额:
    $54.4万
  • 财政年份:
    2020
  • 负责人:
    Robert Neil Eisenman
  • 依托单位:
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
  • 批准号:
    10601282
  • 项目类别:
  • 资助金额:
    $14.73万
  • 财政年份:
    2020
  • 负责人:
    Robert Neil Eisenman
  • 依托单位:
The MYC Transcription Factor Network and the Path to Cancer
  • 批准号:
    10477962
  • 项目类别:
  • 资助金额:
    $103.49万
  • 财政年份:
    2018
  • 负责人:
    Robert Neil Eisenman
  • 依托单位:
The MYC Transcription Factor Network and the Path to Cancer
  • 批准号:
    10601462
  • 项目类别:
  • 资助金额:
    $47.99万
  • 财政年份:
    2018
  • 负责人:
    Robert Neil Eisenman
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: